BIOREGENX, INC.

BioRegenx, Inc.

Company status and history

• Incorporated originally as Findit, Inc. in Nevada on December 23, 1998.
• Effective March 8, 2024, BioRegenx, Inc. merged into Findit, Inc.; the combined company changed its name to BioRegenx, Inc.
• Pursuant to the merger, BioRegenx common shares and Series A preferred were exchanged for 851,977,296 common shares and 3,800 Series A preferred shares of the combined company (representing 90.0% of voting securities).
• Holders of the combined company’s Series A and B preferred shares retired those shares to treasury (representing 98.47% voting control at that time). A majority of shareholders retired 172,197,602 common shares.
• A 16-for-1 split of the combined company’s common shares occurred contemporaneously with the merger. A potential up to 1-for-25 reverse split was contemplated but had not occurred as of the filing.
• The company and its subsidiaries conduct research, development, and commercialization across dietary supplements, medical devices, software, and contactless diagnostic technologies. They are conducting clinical studies under regulatory oversight from the FDA and other authorities. Some offerings are Class I medical devices and are subject to applicable regulatory requirements.

Core business focus

• Research, development, and commercialization of:
  • Dietary supplements
  • Medical devices
  • Software
  • Contactless diagnostic technologies
• Ongoing clinical studies related to various products; regulatory compliance with FDA and other federal and state regulations.
• Telehealth, wellness, and diagnostic activities may implicate professional licensure and patient privacy rules, including HIPAA.

Operating subsidiaries and key activities

DocSun BioMedical Holdings, Inc. (DocSun)

• Acquired January 8, 2024 (agreement effective November 15, 2023; addendum dated December 5, 2023).
• Consideration: 76,800,000 BioRegenx common shares.
• Core technology: DocSun AI Engine combining ballistocardiography, photoplethysmography, optical coherence tomography, and machine learning for vital-sign estimation.
• Contracts: Technical services agreement with a large software company to provide technology services in China, Hong Kong, and Macao; distribution rights associated with DocSun’s engine and SDK.
• Revenue status: To date, DocSun has not yet received fees under the distribution agreement; revenue is expected via licensing and distribution.
• Licensing: World-wide non-exclusive license to NuLife Sciences for use of DocSun technology.

MVHS – Microvascular Health Solutions, LLC (MVHS)

• Focuses on research, product development, sales, and education.
• Key product: Endocalyx Pro™ dietary supplement for microvascular capillary health, produced in a GMP-compliant contract manufacturing facility.
• Offers GlycoCheck™ software and a Class I medical device for microvascular assessment.
• Participates in double-blind placebo studies and holds patents related to Endocalyx Pro.

MyBodyRx, LLC

• Wholly owned subsidiary focused on sales and product development for dietary supplements that complement Endocalyx Pro.

NuLife Sciences, Inc. (NuLife)

• Marketing and distribution arm for MyBodyRx-brand supplements, Endocalyx Pro, GlycoCheck, and other health and wellness devices.
• Sells additional products such as hydrogen water products and devices (Pulsed Electromagnetic Field devices, StimaWELL, ReLounge) through affiliates and practitioners.
• Developing the TruScan.Ai mobile app with DocSun to integrate the DocSun engine for health indications, vitals, nutrients, and skin health.
• Developing the VitalWellness app to integrate a DNA/epigenetics platform with DocSun technology.
• Holds a license agreement with DocSun for development of TruScan.Ai; TruScan.Ai is anticipated for release in Q3 2027.

Findit AI Connect, Inc. (Findit AI)

• Created March 8, 2024; wholly owned subsidiary.
• Owns Findit.com and Classworx.com.
• Findit.com: social media content management platform with an interactive search engine; users can index content and search results across internal and external pages.
• Plans to add an AI component to automate member post generation and distribution across connected platforms.
• Intellectual property: trademarks for Findit, Findit.com, and Classworx.
• Revenue model: monetization through content marketing campaigns, automation tools for affiliates, and white-label licensing of platform tools.

Intellectual property

• Trademarks: Findit, Findit.com, Classworx.
• Patents relating to Endocalyx Pro; ongoing patent filings for other technologies.

Products and revenue sources

• Endocalyx Pro™: dietary supplement targeting microvascular capillary health; sold through MVHS and third-party channels, including medical wholesalers and resellers.
• GlycoCheck™: software system and Class I medical device for microvascular assessment; recurring revenue model based on scans; system package pricing ranges from approximately $14,900 to $32,000.
• MyBodyRx: supplement brand under NuLife designed to complement Endocalyx Pro.
• TruScan.Ai: mobile app and website under development integrating the DocSun engine to provide health indications.
• VitalWellness: app under development to integrate NuLife’s DNA/epigenetics platform with DocSun technology.
• Findit platform: Findit.com and Classworx.com, with planned monetization via AI-assisted content creation and distribution tools for partners and affiliates.

Market approach and channels

• B2B and B2C strategies.
• Academic and clinical partnerships to validate glyco/vascular health approaches.
• Direct-to-consumer channels for supplements and wellness devices.
• Wholesale distribution to medical and wellness practitioners.
• Online marketing and sales channels, including planned use of Amazon, Walmart, and Meta Ads in 2025.

Customers and revenue mix

• Customer types: academic research hospitals and groups, private medical practices, pharmacies, dental practices, wellness practitioners, doctors, healthcare practitioners, patients, consumers, and wholesale distributors.
• GlycoCheck sales generate recurring revenue tied to the number of scans performed.
• Pricing for GlycoCheck packages ranges from approximately $14,900 to $32,000.
• Revenue share arrangements exist with distributors and licensees, including NuLife relationships.
• Geographic revenue concentration: approximately 93% of 2025 revenue from United States customers and approximately 88% in 2024.

Employees and resources

• As of December 31, 2025:
  • 6 full-time employees
  • 8 independent contractors
• The company uses strategic outsourcing and contractors as needed.

Financial highlights

• The company reported an increased emphasis on sales and marketing activity in 2025, including expansion into new online channels (Amazon, Walmart, Meta Ads).
• Geographic revenue concentration by year is provided under Customers and revenue mix.

Regulatory and compliance

• Operations and products are subject to FDA and other federal and state regulations.
• Medical devices, including Class I devices, require appropriate registration/listing, labeling, quality systems, and potential premarket activities.
• Dietary supplements must comply with labeling requirements and Good Manufacturing Practice standards.
• Telehealth, wellness, and diagnostic services may involve professional licensure and patient privacy requirements, including HIPAA.

Other points

• The company qualifies as a Smaller Reporting Company under SEC rules.
• Penny stock regulations may apply to the company’s securities.
• Corporate governance includes cybersecurity oversight through an experienced IT Director; cybersecurity is a standing risk-management topic.

Information sources

• Information is drawn from the company’s SEC filings and annual reports and references the company website (www.bioregenx.com) and the SEC website (www.sec.gov).